Continuing Education Activity

Precocious puberty is defined as the onset of secondary sexual characteristics before age 8 in girls and before age 9 in boys. This definition, endorsed by major pediatric and endocrine societies, remains the standard threshold for initiating further evaluation. Although about 3% of children fall below this statistical threshold and show signs of puberty more than 2 standard deviations earlier than the median age, most cases are benign variants—such as premature thelarche or premature adrenarche—which are self-limited, nonprogressive, and do not require treatment. Only a small subset of children with signs of early puberty exhibit progressive activation of the hypothalamic–pituitary–gonadal axis, warranting evaluation and treatment. True precocious puberty affects approximately 0.2% of girls and fewer than 0.05% of boys. In recent decades, the onset of puberty has shifted earlier, particularly among girls, likely influenced by rising rates of childhood obesity and environmental exposures.

Untreated precocious puberty can have significant consequences, including psychosocial distress, an early growth spurt followed by reduced adult height, and, in some cases, serious underlying pathology requiring urgent medical or surgical attention. Distinguishing benign normal variants from true central precocious puberty remains a clinical challenge, especially in borderline presentations. Effective therapy for central precocious puberty is available in the form of gonadotropin-releasing hormone analogs, whereas treatment options for peripheral precocious puberty are more limited and often less effective. In these cases, a thoughtful, family-centered approach is essential to guide individualized management decisions. This activity reviews the early identification, evaluation, and management of precocious puberty, emphasizing the clinician's role in recognizing the condition and ensuring timely referral to pediatric endocrinology when appropriate.

Objectives:

• Identify clinical red flag features of precocious puberty that warrant further evaluation and referral to a pediatric endocrinologist.
• Evaluate children with signs of precocious puberty using an individualized, evidence-based, patient-centered approach.
• Determine appropriate management options for children with precocious puberty based on the underlying etiology.
• Develop interprofessional team strategies to enhance care coordination and communication, thereby improving outcomes in children with precocious puberty. 

Introduction

Puberty is a complex developmental transition marked by the appearance of secondary sexual characteristics, accelerated growth, and profound physical and psychological changes that culminate in reproductive maturity. A combination of intrinsic factors, such as genetics, and extrinsic factors, including environmental and nutritional influences, plays a role in the onset and progression of puberty.[1] Precocious puberty is defined as the onset of secondary sexual characteristics before age 8 in girls and before age 9 in boys. This definition, endorsed by major pediatric and endocrine societies, remains the standard threshold for initiating a diagnostic evaluation.[2] Although about 3% of children fall below this statistical threshold, showing pubertal signs more than 2 standard deviations earlier than the median age, most cases are benign variants, such as premature thelarche or premature adrenarche, that are self-limited, nonprogressive, and need no treatment.[3] Assessing puberty's clinical context and progression is essential for distinguishing true precocious puberty from normal variants.

There are 2 main types of precocious puberty: central and peripheral. Central precocious puberty results from the premature activation of the hypothalamic–pituitary–gonadal axis, leading to gonadotropin-dependent sexual maturation. Peripheral precocious puberty is gonadotropin-independent and driven by excess sex steroid production from the gonads, adrenals, or exogenous sources. True precocious puberty affects approximately 0.2% of girls and fewer than 0.05% of boys. In recent decades, puberty has started earlier, especially in girls, likely due to increasing childhood obesity and environmental factors.

Untreated precocious puberty can lead to psychosocial issues and reduced adult height due to early epiphyseal closure. Moreover, failing to diagnose precocious puberty promptly may result in the missed detection of severe underlying conditions that require urgent medical or surgical intervention. Differentiating harmless normal variants from true precocious puberty can be challenging, especially in borderline cases. Effective treatment for central precocious puberty is available with gonadotropin-releasing hormone analogs, while options for peripheral precocious puberty are more limited and often less effective. A careful, family-centered approach is essential to guide personalized management decisions in these cases.

Etiology

Puberty results from the activation and maturation of the hypothalamic-pituitary-gonadal (HPG) axis. At birth, there is a brief activation of the HPG axis that leads to increased production of gonadotropins and, subsequently, sex steroids. This phenomenon is known as physiologic "mini-puberty," which usually subsides within 6 months to 2 years. Infant boys may experience temporary enlargement of the testes and penis, increased scrotal pigmentation, and elevated testosterone levels in the blood. Girls may show breast tissue development, vaginal mucosal changes, transient mild pubic hair growth, and detectable serum estradiol and gonadotropins. These typically subtle and self-limited signs resolve as the HPG axis becomes dormant until its next activation during adolescence. The pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. FSH and LH then initiate spermatogenesis and testosterone secretion in males, and oogenesis and estradiol release in females. These changes drive the development of secondary sexual characteristics and reproductive ability.

Evaluation of pubertal disorders requires a clear understanding of pubertal progression terminology. Gonadarche refers to the activation of the gonads, with testicular enlargement being the earliest and most reliable clinical marker of pubertal onset in boys. In girls, thelarche, or breast development in response to estrogen, marks the first sign of puberty. Pubarche signifies the appearance of pubic hair, which reflects increasing adrenal androgen secretion during adrenarche. Adrenarche is characterized by the rising production of dehydroepiandrosterone (DHEA) and its sulfate (DHEAS), contributing to pubarche and axillary hair growth and developing characteristic body odor.

Precocious puberty is broadly classified into 2 categories based on the underlying mechanism:

• Central precocious puberty (gonadotropin-dependent, true or complete precocious puberty)
• Peripheral precocious puberty (gonadotropin-independent, pseudo or incomplete precocious puberty)

The most common form is central precocious puberty (CPP), which is usually idiopathic in girls but more often has a detectable pathological cause in boys, such as lesions in the central nervous system. Benign normal variants include isolated premature thelarche (PT) and premature adrenarche/premature pubarche (PA/PP), which are self-limited, non-progressive conditions that do not involve sustained activation of the hypothalamic-HPG axis and generally do not require treatment.

Causes of CPP include:

• Congenital disorders: Cerebral palsy and congenital hydrocephalus
• Central nervous system (CNS) tumors: Hypothalamic hamartoma, optic glioma, arachnoid cysts, astrocytoma, ependymoma, acquired hydrocephalus, septo-optic dysplasia, and pineal tumors
• CNS injury: Head trauma, cranial irradiation, cerebral palsy, and infections (Tuberculous meningitis/tuberculoma)
• Genetics: Loss of function mutation encoding the MKRN3 (makorin ring finger protein 3) gene, a gain of function mutation encoding the kisspeptin (KISS1) and its receptor (KISSR) genes [4][5][6] 
• Congenital conditions: Neurofibromatosis type 1, Sturge-Weber syndrome, and tuberous sclerosis
• Environmental: Internationally adopted children, withdrawal from sex steroid therapy, and endocrine disruptors

  • Many internationally adopted children experience undernutrition early in life, followed by rapid weight gain after adoption. Accelerated growth and increased fat mass can trigger early HPG axis activation. Exposure to endocrine-disrupting chemicals, such as bisphenol A, phthalates, polychlorinated biphenyls, dioxins, certain pesticides, and heavy metals, can interfere with hormonal signaling and have been associated with an earlier onset of puberty.
• Familial precocious puberty
• Idiopathic CPP: Characterized by progressive development of secondary sexual characteristics, accelerated linear growth, advanced bone age, and sustained activation of the HPG axis without an identifiable cause

Causes of peripheral precocious puberty (PPP), where sex steroids originate from the gonads, adrenal glands, ectopically, or exogenously, include:

• Congenital adrenal hyperplasia
• McCune-Albright syndrome 
• Gonadal tumors: Feminizing benign ovarian cyst (females only), sex cord-stromal tumors, such as germ cell tumors, such as dysgerminoma, teratoma, and embryonal tumors producing sex steroids
• Adrenocortical tumors
• Familial male-limited precocious puberty (testotoxicosis), Leydig cell tumors, HCG-producing tumors (males only)
• Exogenous exposure to sex steroids
• Van Wyk and Grumbach syndrome (severe hypothyroidism leading to pseudoprecocity)
• Aromatase excess syndrome (females only)
• Isolated vaginal bleeding: May suggest foreign body, sexual abuse, or tumors of the genital tract, or extreme variation of normal intermittent ovarian activation [7][8]

Epidemiology

Historically, precocious puberty has been defined as the development of secondary sexual characteristics before age 8 in girls and age 9 in boys. However, secular trends indicate an earlier onset of puberty in girls worldwide. A meta-analysis of 30 recent studies showed a decrease in the age of thelarche by 0.24 years per decade (95% CI, -0.44 to -0.04; approximately 3 months) from 1977 to 2013, with variations by race, ethnicity, and geography.[9] Recent large-scale registry studies have noted a significant increase in the annual incidence of central CPP over the past 2 decades.[10]

The timing of puberty varies among populations and is affected by biological and environmental factors. Adiposity significantly influences higher body fat levels associated with earlier pubertal onset, especially in girls.[11][12] Racial and ethnic differences are also evident; for example, Black girls tend to enter puberty earlier than their peers, leading some experts to recommend a lower diagnostic cutoff of 6 years in this group. Additionally, menarche before age 9.5 years is sometimes used as an alternative criterion for identifying precocious puberty in girls.

A landmark United States study from 1997 reported that by age 7, approximately 7% of White girls and 15% of Black girls had clinical signs of puberty; by age 8, these figures rose to 27% and 48%, respectively.[13] More recently, results from a 2022 study showed that by age 8, thelarche was evident in 10.5% of White girls and 37.8% of Black girls.[14] These data suggest that racial and ethnic disparities persist in the timing of puberty, possibly accentuated by changing environmental, nutritional, and obesity-related factors.

Precocious puberty is much more common in girls, with a female-to-male ratio of about 10:1.[15] An early study published in 2005, based on data from a Danish national registry, estimated that 0.2% of females experienced some form of precocious puberty (CPP, PPP, or benign variants). In comparison, less than 0.05% of males were affected. The study showed a female predominance, roughly 20 to 23 cases per 10,000 girls, compared to fewer than 5 cases per 10,000 boys.[16] More recent research indicates that CPP is around 15 times more common in girls than boys, with rates ranging from 29 per 100,000 girls in the United States to 92 per 100,000 girls in Denmark.[13][16]

Notably, PPP is diagnosed much less frequently than CPP; an Iranian case series (2012) found PPP in about 23% of children with precocious puberty.[17] A Spanish observational study (2010) estimated the annual incidence of CPP to range from 0.02 to 1.07 cases per 100,000 people.[18] In Korea, the prevalence of CPP was reported as 55.9 per 100,000 girls and 1.7 per 100,000 boys, with an annual incidence of 15.3 per 100,000 girls and 0.6 per 100,000 boys.[19] These figures highlight significant variability across populations, making precise estimates difficult. 

Pathophysiology

Central Precocious Puberty

CPP begins with the activation of the gonadostat in the hypothalamus, followed by the activation of the pituitary and gonads. This condition is also called gonadotropin-dependent precocious puberty. Since its onset and development resemble normal puberty, it is considered true precocious puberty. Complete precocious puberty involves the early and progressive appearance of all pubertal signs in their usual order, including thelarche in girls, testicular enlargement in boys, adrenarche and pubarche in both sexes, and menarche or spermarche in females and males, respectively. Complete CPP is isosexual, meaning affected individuals develop secondary sexual characteristics consistent with their gender. In most cases (90%–95%), CPP in girls is idiopathic, while in boys it is more often linked to an underlying medical condition. A single-center Chinese study found that out of 82 boys with precocious puberty, 62 (75.6%) were diagnosed with CPP, and 20 (24.4%) with PPP. Among those with CPP, 49 of 62 cases were classified as idiopathic CPP, with the remaining 13 having known etiologies.[7]

Any intracranial disturbance can cause CPP by increasing excitatory inputs or disrupting CNS inhibition of hypothalamic GnRH secretion (see below). This may result from transforming growth factor-beta (TGF-β), trauma, chronic inflammatory disorders, intracranial masses, or congenital conditions. The most common brain lesion leading to CPP is a hypothalamic hamartoma. The ectopic neural cells within the lesion act as an accessory GnRH pulse generator. Affected patients typically present with precocious puberty in infancy, sometimes as early as 12 months old. The most characteristic feature is gelastic seizures, a rare type of seizure characterized by sudden, uncontrollable bouts of laughter that are often inappropriate or unprovoked. These seizures are generally resistant to medication. Other features associated with hypothalamic hamartomas include cognitive, behavioral, and psychiatric symptoms. Notably, there is a higher prevalence among internationally adopted children. The exact mechanism remains unknown, but it may be related to improved nutrition and exposure to endocrine-disrupting chemicals after adoption.

Recent years have seen the emergence of gain-of-function mutations in the KISS1 gene and its receptor, KISS1R, and loss-of-function mutations in the MKRN3 and DLK1 genes, leading to familial forms of central precocious puberty. Additionally, 1p36 deletion, 7q11.23 microdeletion (Williams-Beuren syndrome), 9p deletion, maternal uniparental disomy of chromosomes 7 (Silver-Russell syndrome) and 14 (Temple syndrome), de novo interstitial deletion, maternal uniparental disomy of chromosome 15 (Prader-Willi syndrome), and a de novo deletion in the cyclin-dependent kinase-like 5 gene (CDKL5; phenotype like Rett syndrome) are known genetic associations of precocious puberty.[4][5][6] 

In some cases, CPP develops secondary to a virilizing or feminizing disorder that initially caused PPP with significantly advanced bone age (10–12 years). Treating the underlying PPP lowers sex steroid levels, removing the inhibitory feedback on the hypothalamic-pituitary-gonadal axis and enabling its activation. Conditions such as congenital adrenal hyperplasia, McCune-Albright syndrome, or sex steroid–secreting tumors hasten skeletal maturation. Once bone age reaches the threshold for normal pubertal onset, the transition to CPP may occur.[15]

Peripheral Precocious Puberty 

Exposure to excess endogenous or exogenous sex steroids, independent of hypothalamic GnRH stimulation, causes PPP. The pathophysiology of PPP, which occurs less frequently than CPP, mainly depends on its distinct etiology. The 3 leading causes of PPP are congenital adrenal hyperplasia, germ cell tumors, and familial male-limited PPP.[7] Congenital adrenal hyperplasia, the most common cause of peripheral precocious puberty, results in early androgen excess independent of hypothalamic–pituitary–gonadal axis activation.[15] The most common form, 21-hydroxylase deficiency, impairs cortisol synthesis, leading to the loss of negative feedback and increased secretion of adrenocorticotropic hormone (ACTH). This chronic ACTH stimulation causes the adrenal cortex to overproduce androgen precursors, which are then converted to androgens such as testosterone and androstenedione, resulting in the characteristic signs and symptoms of PPP. 

Ovarian tumors (eg, granulosa cell tumors) in girls can secrete estrogens, leading to premature breast development, vaginal bleeding, and advanced bone age. In boys, testicular tumors (eg, Leydig cell tumors) cause PPP by secreting sex steroids, mainly testosterone, or less commonly, hCG, which stimulates Leydig cells to produce testosterone, resulting in early virilization without testicular enlargement or elevated gonadotropin levels. In both boys and girls, adrenal adenomas and carcinomas can secrete testosterone, estrogens, and androgen precursors, leading to early signs of virilization such as pubic hair development, penile enlargement, and accelerated growth. These tumor-produced hormones suppress the production of GnRH, LH, and FSH, which helps distinguish PPP from CPP. Germ cell tumors, hepatoblastomas, pineal gland tumors, and mediastinal tumors can also produce hCG, which stimulates LH receptors and increases testosterone production and virilization. 

Familial male-limited precocious puberty, also called testotoxicosis, is a rare autosomal dominant disorder characterized by PPP in boys; this results from a germline activating mutation of the LH receptor gene, which triggers Leydig cell activation and increased testosterone levels. McCune-Albright syndrome is another cause of PPP. This syndrome is a sporadic disorder caused by an activating mutation of the GNAS1 gene, which encodes the alpha subunit of the G protein. This mutation increases cAMP production, resulting in the hyperfunction of multiple cyclic adenosine monophosphate-dependent receptors. The classic triad includes "coast of Maine" café-au-lait macules, polyostotic fibrous dysplasia, and precocious puberty; however, precocious puberty or even a monostotic form of fibrous dysplasia may present without characteristic cutaneous findings. Additional endocrine manifestations include hyperthyroidism, Cushing syndrome, and growth hormone excess.[8]

Another infrequent cause of PPP is Van Wyk and Grumbach syndrome, characterized by primary hypothyroidism, ovarian cysts, delayed bone age, and precocious puberty. Researchers propose that this phenomenon may result from extreme TSH elevations that aberrantly stimulate ovarian FSH receptors ("specificity spillover"), similar to the rare ovarian hyperstimulation syndrome seen when pregnancy-level hCG activates FSH receptors. Concurrent hyperprolactinemia may further enhance ovarian sensitivity to LH, amplifying the effect.[16]

Histopathology

CPP is idiopathic in most girls. In the remaining girls and in a larger proportion of boys, it is associated with midline lesions such as hypothalamic hamartomas, germinomas, or other tumors. The histopathology of both CPP and PPP varies according to the underlying etiology.

• Ovarian cysts: Follicular cysts appear histologically as thin-walled cysts containing follicular fluid, lined by granulosa and theca interna cells.
• Ovarian tumors: The appearance of granulosa cell tumors varies depending on the type of cells (adult vs juvenile). Adult-type granulosa cells appear as elongated pale cells with scant cytoplasm and grooved nuclei. These cells often appear as rosettes around collections of eosinophilic fluid referred to as "Call-Exner bodies" and resemble primordial follicles. Juvenile-type granulosa cells appear as immature cells with frequent mitotic activity.[18]
• Leydig cell tumors: Histologically, Leydig cell tumors appear as groups of large cells with regular, round nuclei and eosinophilic cytoplasm. Eosinophilic cytoplasmic inclusions, referred to as Reinke crystals, may also be seen.
• Congenital adrenal hyperplasia: Histological features include diffuse cortical hyperplasia and cytoplasmic vacuolization. 

History and Physical

A detailed history and physical examination are essential for differentiating true precocious puberty from benign normal variants by assessing the onset, tempo, and sequence of pubertal development, while also providing critical clues to the specific underlying pathologic etiologies when signs of CPP and PPP are present. The progressive development of multiple secondary sexual characteristics, rapid linear growth, and an advanced bone age characterize true precocious puberty. In contrast, benign normal variants typically present with isolated, non-progressive signs, a normal growth rate, and a bone age appropriate for the chronological age.[2]

Clinicians should thoroughly document the onset and progression of pubertal signs and gather a detailed family history of pubertal timing in parents and siblings, which may indicate a familial pattern. Notably, rapid puberty progression, even if it starts at a typical age, is considered abnormal.[4][5][6][15] Inquiry should also include neurological symptoms such as headaches, seizures, increased head circumference, visual or cognitive changes, abnormal behaviors, or episodes of inappropriate laughter (which may suggest hypothalamic hamartoma). Additional relevant history includes previous head trauma, treatment for brain tumors (surgery or irradiation), or central nervous system infections, along with signs of anterior or posterior pituitary dysfunction, such as polyuria, polydipsia, or decreased growth velocity. Clinicians should also ask about any exposure, whether intentional or accidental, to sex hormone-containing creams, pills, or supplements. A review of systems positive for lower abdominal pain could indicate ovarian pathology.

Children with precocious puberty show the typical signs of puberty, but these features appear earlier than expected for their age. The early clinical signs are breast development in girls and increased testicular size (equal to or greater than 4 mL as measured by an orchidometer) in boys. Rapid linear growth is a key indicator of early puberty. Clinicians must accurately record height, weight, growth rate (in centimeters per year), and body mass index. Reviewing the patient's growth chart can reveal specific issues, such as short stature, which may be linked to conditions like Van Wyk and Grumbach syndrome. Conversely, lacking a suitable growth spurt during puberty could suggest growth hormone deficiency.

The physical exam should evaluate pubic and axillary hair and signs of virilization or feminization, including clitoromegaly, penile enlargement, acne, and body odor, which may suggest an androgen-secreting adrenal tumor. Clinicians should also perform a comprehensive neurologic exam, especially if central nervous system pathology is suspected. In boys and girls with pubic hair and body odor, the absence of increased testicular size or the presence of menarche with minimal breast development should prompt investigation of peripheral causes. Unilateral testicular enlargement may occur with testicular tumors. A skin exam identifying café au lait macules, neurofibromas, or bony deformities may indicate specific diagnoses such as neurofibromatosis type 1 or McCune-Albright syndrome.   

Evaluation

Once a child's development is classified as either true precocious or early normal puberty, the scope of evaluation is guided by age at onset, presence of predisposing factors (such as adiposity, family history, or rapid progression), and the pace of pubertal changes. The next step is to identify the source of sex steroid exposure, whether it is central (HPG axis–mediated), peripheral (autonomous adrenal or gonadal secretion), or exogenous. Initial diagnostic tests include bone age assessment, measurement of LH, FSH, and estrogen/testosterone levels, dehydroepiandrosterone sulfate (DHEA-S) levels, 17-OH progesterone levels, and thyroid function tests. Some clinicians perform a bone age test before blood work because it is noninvasive and easy. When the bone age is advanced (more than 2 standard deviations) compared to the chronological age, further testing should follow.

Hormonal testing helps differentiate between peripheral and central causes of precocious puberty. This is measured using ultrasensitive immunochemiluminometric assays (ICMA) with a sensitivity of 0.01 U/L or electrochemiluminiscence assay (ECLIA) with a 0.1 IU/L sensitivity. Serum LH concentrations greater than 0.2 to 0.3 IU/L can indicate pubertal development. Prepubertal and pubertal hormone levels can overlap, with LH values reported ranging from 0.3 to 0.83 IU/L; therefore, stimulation testing may be necessary based on the clinical presentation. Cut-off values for LH after stimulation with GnRH or a GnRH analog, indicating activation of the pubertal HPG axis, depend on the stimulus type, the timing of sample collection, and the assay used, with reported ranges from greater than 3.3 to 9.2 IU/L.[19] Additionally, serum E2 levels after 24 hours of GnRH agonist stimulation increase the test's sensitivity. FSH levels have limited usefulness. GnRH stimulation results in infant girls should be interpreted with caution, as higher baseline and stimulated LH levels may indicate physiological mini-puberty rather than true CPP. A ratio of LH/FSH less than 0.43 suggests prepubertal status.[20] A stimulated LH/FSH ratio of more than 0.66 has also been proposed to distinguish between progressive and nonprogressive benign variants.[21]

Markedly elevated estradiol in girls or testosterone in boys, accompanied by suppressed LH and FSH, indicates peripheral precocity. Measuring adrenal androgens, such as DHEA-S, helps differentiate adrenal from testicular sources of androgen excess. In boys, clinicians should measure human hCG, as certain germ cell tumors secrete hCG, which stimulates LH receptors and promotes testosterone production. In cases of PPP, pelvic ultrasonography may detect ovarian tumors or cysts in females, while testicular ultrasonography in males may reveal nonpalpable Leydig cell tumors. A pelvic ultrasound can also assess the maturity level of the uterus and ovaries, providing additional information about puberty and premature thelarche. Computed tomography of the abdomen and pelvis may be necessary in suspected PPP cases to locate the source of sex steroids.

A bone scan can be helpful in specific cases to identify subclinical fibrous dysplasia when there are no obvious bone deformities but a strong suspicion of McCune-Albright syndrome. Genetic testing of relevant genes can help confirm the diagnosis in suspected cases of familial precocity, especially in boys when familial male-limited precocious puberty is suspected. MRI of the hypothalamic-pituitary axis is recommended for cases of CPP, with the highest diagnostic yield seen in children under 6 years old, those with neurological signs, and boys of any age. For girls, a pelvic ultrasound showing uterine lengths greater than 3.5 to 4 cm and ovarian volumes exceeding 2 mL indicates the onset of puberty. 

Treatment / Management

Clinicians should distinguish children with benign variants of puberty, such as isolated premature thelarche or menarche in girls, or premature adrenarche in both sexes, which require no intervention beyond reassurance and watchful waiting. Similarly, some cases of early but normal puberty in girls (ages 6–8 years, with higher height centiles, absence of neurologic signs, and normal tempo of progression) generally do not benefit from treatment, and observation with reassurance is appropriate. In other cases, management should be guided by the underlying cause of puberty.

Central Precocious Puberty

The primary goals of treatment are to maximize final adult height and alleviate the associated psychosocial stresses of developing before one's peers. The decision to treat depends on the child's age and the progression of puberty. If the child has the onset of puberty younger than age 6 to 7, and/or there is a rapid tempo of puberty, or if the bone age is significantly advanced, treatment with GnRH agonists is the standard of care.[19][22] Different formulations (intramuscular and subcutaneous) of long and short-acting GnRH agonists exist, and the choice depends on the patient's and clinician's preference. Depot formulations are usually preferred, given every 4 or 12 weeks. A depot formulation is a long-acting preparation designed to slowly release medication from the injection site, maintaining consistent systemic levels and reducing the need for frequent dosing. A 12-week depot injection provides therapeutic effect for about three months. The most commonly used option in the United States is leuprolide acetate, administered as a 12-week depot injection. Treatment should continue, uninterrupted, until the child reaches a bone age of 12.5 years in girls and 14 years in boys. Treatment can be discontinued earlier if the family and child are satisfied with the expected height and ready to resume puberty. Menstrual bleeding may occur from a few months to more than 2 years after the cessation of treatment. [19]

GnRH agonist therapy is generally considered safe, with no reported significant adverse effects. The most common adverse events include local skin reactions (intramuscular pain, sterile abscesses) and menopausal-like symptoms (hot flushes). There have been long-term concerns about possible decreased bone mineral density, polycystic ovarian syndrome, and increased body mass index, but these remain unproven. Withdrawal bleeding is common in girls with advanced maturation, and progesterone depot injections for the initial few weeks can prevent or minimize this.

Children must periodically monitor pubertal progression, growth velocity, and skeletal maturation during treatment to ensure optimal outcomes. During treatment, measurement of LH in combination with estrogen or testosterone levels helps guide monitoring alongside clinical findings and bone age. The ratio of change in bone age to change in chronological age over time (Δbone age/Δchronological age) is the best predictor of treatment response. Height growth benefits depend on the patient's age and bone age advancement at the time treatment is begun, the duration of therapy, and the response to therapy. [23] A recent meta-analysis suggested a 0.63 (0.17-1.08) SDS benefit compared to pretreatment predictions.[9] 

Peripheral Precocious Puberty

Treatment focuses on eliminating the source of endogenous or exogenous sex steroids. Surgery is recommended for gonadal and adrenal tumors that produce sex steroids. Tumors that secrete HCG require surgical removal and may, depending on stage and pathology, need adjuvant radiotherapy or chemotherapy. Any external sources of sex steroids should also be removed. Classic congenital adrenal hyperplasia (CAH) is treated with glucocorticoids. In patients with McCune-Albright syndrome, some benefit is seen with aromatase inhibitors (anastrozole, letrozole) and selective estrogen receptor modulators (tamoxifen) in girls. Meanwhile, treatment in boys is similar to familial male-limited precocious puberty (FMPP, testotoxicosis). The optimal treatment for FMPP is not well established; however, most centers recommend combining an androgen antagonist (eg, spironolactone, bicalutamide) with an aromatase inhibitor (eg, anastrozole, letrozole). The addition of a GnRH analog has been shown to help preserve final adult development height.[8][24] Children with hypothyroidism benefit from a levothyroxine supplement, which can reduce pubertal signs. Children with peripheral precocious puberty of any cause are at risk of developing CPP when treated for their primary disorder. If this occurs, additional GnRH analog treatment is necessary to halt the progression of secondary CPP.

Differential Diagnosis

True precocious puberty requires differentiation from the benign forms of early puberty.[25] 

• Premature Thelarche is the unilateral or bilateral development of breast tissue in girls between birth and 24 months, or between 6 and 8 years, with a bimodal peak; this is the most common among benign variants of precocious puberty.[26] There are no other associated pubertal changes. Bone age, growth velocity, and biochemical testing are normal. Frequent clinical follow-up is required to monitor growth and pubertal progression. No intervention is needed beyond reassurance and watchful waiting.
• Premature adrenarche refers to the early production of adrenal androgens, which characterizes this benign condition. Patients present with pubic or axillary hair, body odor, or acne before age 8. There is no breast development in girls and no testicular enlargement in boys. Bone age is seldom advanced. Clinicians must rule out exposure to exogenous and endogenous androgen sources, such as creams or gels, adrenal tumors, and late-onset CAH.
• Isolated premature menarche refers to the onset of vaginal bleeding in girls younger than 8 who have no other pubertal signs. They may present with either a single episode or a few cycles of bleeding and have a normal progression of puberty at a later time. Recent studies have not demonstrated any effect on ultimate adult height. Sexual abuse, vaginal foreign bodies, tumors of the genital tract, and infections of the vulva and vagina may also cause isolated vaginal bleeding and must be ruled out. 
• Lipomastia, excess adipose tissue in the breast, may sometimes be confused with premature thelarche/precocious puberty in girls with obesity and requires a thorough clinical assessment. 

Prognosis

The prognosis of precocious puberty in girls who present with premature menarche and other early signs of pubertal development depends on whether the process is progressive, the underlying etiology, and the timing and duration of treatment. In true CPP cases, where there is early activation of the hypothalamic-pituitary-gonadal axis, untreated progression can result in short adult stature due to early epiphyseal closure, early menarche, and a higher risk of negative psychosocial outcomes such as anxiety, depression, and engagement in risky behaviors at an earlier age. There is also evidence linking early puberty to increased long-term risks like obesity, metabolic syndrome, and breast cancer in menarche.[27] The prognosis of precocious puberty in boys depends on the underlying etiology, the pubertal progression rate, and the timing and effectiveness of the intervention. 

The primary long-term concern in both girls and boys is reduced adult height caused by accelerated bone maturation and early epiphyseal closure when precocious puberty is untreated. Early initiation of treatment is typically associated with a greater likelihood of preserving final adult height. Outcomes depend on several factors, including the advancement of bone age, the age at which precocious puberty begins, the timing of treatment start, and the length of therapy.[28] Two systematic reviews in the recent past suggested a height benefit of 0.63 (0.17-1.08) SDS and a mean difference (MD) of 4.83 cm (2.32-7.34 cm), compared to pretreatment predictions and untreated girls, respectively.[9][29] The HPG axis returns to normal after the cessation of therapy, and these children typically experience a normal progression of puberty upon discontinuation of treatment. GnRH analog therapy is considered safe in terms of its long-term effects on fertility, weight, body mass index, and metabolic bone health outcomes. More data and longer-term follow-up are needed for some concerns regarding possible PCOS and the psychological effects of treatment versus no treatment.[19][29][30] For patients with PPP, the prognosis depends on the underlying cause of the sex hormone exposure and whether it is treated effectively. 

Complications

Complications can arise from precocious puberty and its associated conditions or the treatment itself. Untreated precocious puberty often leads to a shorter adult height, early menarche in girls, and frequently emotional challenges. Some research suggests that children with precocious puberty are more likely to show conduct problems, social withdrawal, truancy, substance abuse, or have multiple sexual partners. They may also face peer pressure and concerns about their self-image, although most of these issues tend to resolve by early adulthood.[31] Further studies are needed to validate the psychological consequences in these patients.[32]

Complications from treatment with GnRH analogs are rare; studies have shown safety both in the short and long term. Patients might experience headaches, hot flushes, mood swings, fatigue, and local reactions at the injection site. During treatment, lean muscle mass and bone mineral density may be reduced; however, these changes typically return to normal after treatment is stopped.[15] 

Deterrence and Patient Education

Primary care clinicians and pediatric endocrinologists should thoroughly discuss early pubertal changes with families, even when a benign variant is identified. This discussion should cover:

• Discuss the normal progression of puberty and how to differentiate between benign and abnormal variants.
• If treatment is indicated, the goals of therapy, anticipated duration, potential adverse effects, and monitoring requirements should be discussed.
• Communicating with the child and family in an age-appropriate, reassuring manner to minimize anxiety about the diagnosis and treatment plan.[33]
• Discuss psychosocial considerations, including peer interactions, self-esteem, and body image.

Families should receive written educational resources to reinforce these discussions and provide ongoing support. Recommended materials are available through the Pediatric Endocrine Society/American Academy of Pediatrics Patient Education Committee, Section on Endocrinology, which offers evidence-based guidance for parents and children.

Enhancing Healthcare Team Outcomes

The prevalence of precocious puberty appears to be increasing, influenced by genetic predisposition, childhood obesity, and environmental exposures to endocrine-disrupting chemicals. Effective management requires a patient-centered, ethically grounded, interprofessional team approach that emphasizes accurate diagnosis, evidence-based treatment strategies, and coordinated follow-up. Pediatric endocrinologists, general pediatricians, family physicians, and advanced practitioners contribute their diagnostic expertise, interpret complex endocrine testing, and guide therapeutic decision-making. Nurses provide primary assessment, reinforce education, monitor treatment adherence and side effects, and serve as liaisons between the family and the broader care team. Pharmacists ensure safe dispensing of GnRH analogs and other therapies, identify potential drug interactions, and help families navigate insurance barriers. Mental health professionals address psychosocial stressors, stigma, and body image concerns while providing strategies to enhance coping and resilience. Surgeons, radiologists, laboratory medicine specialists, and clinical geneticists collaborate to evaluate and manage complex or tumor-related cases.

Interprofessional collaboration requires clear communication, respect for each team member's expertise, and shared responsibility for decision-making. Ethical responsibilities include ensuring informed consent, involving families in care planning, balancing the benefits and risks of therapy, and avoiding overtreatment for patients with benign variants. Care coordination encompasses timely referrals, the integration of school support when necessary, and longitudinal surveillance, given the lifelong health implications of many underlying conditions that cause precocious puberty. By aligning clinical skills with communication strategies and ethical principles, interprofessional teams enhance patient safety, optimize health outcomes, and deliver comprehensive, family-centered care for children with precocious puberty.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Kiess W, Hoppmann J, Gesing J, Penke M, Körner A, Kratzsch J, Pfaeffle R. Puberty - genes, environment and clinical issues. J Pediatr Endocrinol Metab. 2016 Nov 01;29(11):1229-1231. [PubMed: 27771625]

2.

Cheuiche AV, da Silveira LG, de Paula LCP, Lucena IRS, Silveiro SP. Diagnosis and management of precocious sexual maturation: an updated review. Eur J Pediatr. 2021 Oct;180(10):3073-3087. [PubMed: 33745030]

3.

Liang X, Huang K, Dong G, Chen R, Chen S, Zheng R, Wang C, Wei H, Cao B, Liang Y, Yao H, Su Z, Maimaiti M, Luo F, Li P, Zhu M, Du H, Yang Y, Cui L, Si S, Bai G, Yu Y, Wang EG, Hofman PL, Fu J. Current Pubertal Development in Chinese Children and the Impact of Overnutrition, Lifestyle, and Perinatal Factors. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2282-2289. [PubMed: 36881937]

4.

Abreu AP, Dauber A, Macedo DB, Noel SD, Brito VN, Gill JC, Cukier P, Thompson IR, Navarro VM, Gagliardi PC, Rodrigues T, Kochi C, Longui CA, Beckers D, de Zegher F, Montenegro LR, Mendonca BB, Carroll RS, Hirschhorn JN, Latronico AC, Kaiser UB. Central precocious puberty caused by mutations in the imprinted gene MKRN3. N Engl J Med. 2013 Jun 27;368(26):2467-75. [PMC free article: PMC3808195] [PubMed: 23738509]

5.

Palumbo S, Cirillo G, Aiello F, Papparella A, Miraglia Del Giudice E, Grandone A. MKRN3 role in regulating pubertal onset: the state of art of functional studies. Front Endocrinol (Lausanne). 2022;13:991322. [PMC free article: PMC9523110] [PubMed: 36187104]

6.

Shim YS, Lee HS, Hwang JS. Genetic factors in precocious puberty. Clin Exp Pediatr. 2022 Apr;65(4):172-181. [PMC free article: PMC8990949] [PubMed: 34665958]

7.

Ziqin L, Xiaohui L, Xiaobo C. Precocious Puberty in Boys: A Study Based on Five Years of Data from a Single Center in Northern China. J Clin Res Pediatr Endocrinol. 2021 Nov 25;13(4):418-425. [PMC free article: PMC8638629] [PubMed: 34013711]

8.

Haddad NG, Eugster EA. Peripheral precocious puberty including congenital adrenal hyperplasia: causes, consequences, management and outcomes. Best Pract Res Clin Endocrinol Metab. 2019 Jun;33(3):101273. [PubMed: 31027974]

9.

Eckert-Lind C, Busch AS, Petersen JH, Biro FM, Butler G, Bräuner EV, Juul A. Worldwide Secular Trends in Age at Pubertal Onset Assessed by Breast Development Among Girls: A Systematic Review and Meta-analysis. JAMA Pediatr. 2020 Apr 01;174(4):e195881. [PMC free article: PMC7042934] [PubMed: 32040143]

10.

Bräuner EV, Busch AS, Eckert-Lind C, Koch T, Hickey M, Juul A. Trends in the Incidence of Central Precocious Puberty and Normal Variant Puberty Among Children in Denmark, 1998 to 2017. JAMA Netw Open. 2020 Oct 01;3(10):e2015665. [PMC free article: PMC7550972] [PubMed: 33044548]

11.

Deardorff J, Reeves JW, Hyland C, Tilles S, Rauch S, Kogut K, Greenspan LC, Shirtcliff E, Lustig RH, Eskenazi B, Harley K. Childhood Overweight and Obesity and Pubertal Onset Among Mexican-American Boys and Girls in the CHAMACOS Longitudinal Study. Am J Epidemiol. 2022 Jan 01;191(1):7-16. [PMC free article: PMC8837899] [PubMed: 33831178]

12.

Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics. 2009 Jan;123(1):84-8. [PubMed: 19117864]

13.

Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG, Hasemeier CM. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997 Apr;99(4):505-12. [PubMed: 9093289]

14.

Osinubi AA, Lewis-de Los Angeles CP, Poitevien P, Topor LS. Are Black Girls Exhibiting Puberty Earlier? Examining Implications of Race-Based Guidelines. Pediatrics. 2022 Aug 01;150(2) [PubMed: 35909158]

15.

Carel JC, Léger J. Clinical practice. Precocious puberty. N Engl J Med. 2008 May 29;358(22):2366-77. [PubMed: 18509122]

16.

Christens A, Sevenants L, Toelen J, Bullens D, Casteels K. Van Wyk and Grumbach syndrome: an unusual form of precocious puberty. Gynecol Endocrinol. 2014 Apr;30(4):272-6. [PubMed: 24568556]

17.

Rohani F, Salehpur S, Saffari F. Etiology of precocious puberty, 10 years study in Endocrine Reserch Centre (Firouzgar), Tehran. Iran J Reprod Med. 2012 Jan;10(1):1-6. [PMC free article: PMC4163256] [PubMed: 25242967]

18.

Looijenga LHJ, Kao CS, Idrees MT. Predicting Gonadal Germ Cell Cancer in People with Disorders of Sex Development; Insights from Developmental Biology. Int J Mol Sci. 2019 Oct 10;20(20) [PMC free article: PMC6834166] [PubMed: 31658757]

19.

Bangalore Krishna K, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, Charmandari E, Lee PA, Freire AV, Ropelato MG, Yazid Jalaludin M, Mbogo J, Kanaka-Gantenbein C, Luo X, Eugster EA, Klein KO, Vogiatzi MG, Reifschneider K, Bamba V, Garcia Rudaz C, Kaplowitz P, Backeljauw P, Allen DB, Palmert MR, Harrington J, Guerra-Junior G, Stanley T, Torres Tamayo M, Miranda Lora AL, Bajpai A, Silverman LA, Miller BS, Dayal A, Horikawa R, Oberfield S, Rogol AD, Tajima T, Popovic J, Witchel SF, Rosenthal SM, Finlayson C, Hannema SE, Castilla-Peon MF, Mericq V, Medina Bravo PG. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium. Horm Res Paediatr. 2019;91(6):357-372. [PubMed: 31319416]

20.

Vestergaard ET, Schjørring ME, Kamperis K, Petersen KK, Rittig S, Juul A, Kristensen K, Birkebæk NH. The follicle-stimulating hormone (FSH) and luteinizing hormone (LH) response to a gonadotropin-releasing hormone analogue test in healthy prepubertal girls aged 10 months to 6 years. Eur J Endocrinol. 2017 Jun;176(6):747-753. [PubMed: 28348072]

21.

Howard SR. Interpretation of reproductive hormones before, during and after the pubertal transition-Identifying health and disordered puberty. Clin Endocrinol (Oxf). 2021 Nov;95(5):702-715. [PMC free article: PMC9291332] [PubMed: 34368982]

22.

Aguirre RS, Eugster EA. Central precocious puberty: From genetics to treatment. Best Pract Res Clin Endocrinol Metab. 2018 Aug;32(4):343-354. [PubMed: 30086862]

23.

Ouyang L, Lu Y, Lin L, Yang F. Growth pattern, growth deceleration, and relevant predictors in girls treated with GnRHa: a retrospective longitudinal study. J Pediatr Endocrinol Metab. 2024 Sep 25;37(9):779-788. [PubMed: 39135509]

24.

Leschek EW, Flor AC, Bryant JC, Jones JV, Barnes KM, Cutler GB. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty. J Pediatr. 2017 Nov;190:229-235. [PMC free article: PMC5726420] [PubMed: 29144249]

25.

Berberoğlu M. Precocious puberty and normal variant puberty: definition, etiology, diagnosis and current management. J Clin Res Pediatr Endocrinol. 2009;1(4):164-74. [PMC free article: PMC3005651] [PubMed: 21274291]

26.

de Vries L, Guz-Mark A, Lazar L, Reches A, Phillip M. Premature thelarche: age at presentation affects clinical course but not clinical characteristics or risk to progress to precocious puberty. J Pediatr. 2010 Mar;156(3):466-71. [PubMed: 19914634]

27.

Soriano-Guillén L, Argente J. Central precocious puberty, functional and tumor-related. Best Pract Res Clin Endocrinol Metab. 2019 Jun;33(3):101262. [PubMed: 30733078]

28.

Guaraldi F, Beccuti G, Gori D, Ghizzoni L. MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol. 2016 Mar;174(3):R79-87. [PubMed: 26466612]

29.

Luo X, Liang Y, Hou L, Wu W, Ying Y, Ye F. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021 May;94(5):786-796. [PMC free article: PMC8248422] [PubMed: 33387371]

30.

Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013 Jun;98(6):2198-207. [PubMed: 23515450]

31.

Copeland W, Shanahan L, Miller S, Costello EJ, Angold A, Maughan B. Outcomes of early pubertal timing in young women: a prospective population-based study. Am J Psychiatry. 2010 Oct;167(10):1218-25. [PMC free article: PMC2992443] [PubMed: 20478880]

32.

Zevin EL, Eugster EA. Central precocious puberty: a review of diagnosis, treatment, and outcomes. Lancet Child Adolesc Health. 2023 Dec;7(12):886-896. [PubMed: 37973253]

33.

Kletter GB, Klein KO, Wong YY. A pediatrician's guide to central precocious puberty. Clin Pediatr (Phila). 2015 May;54(5):414-24. [PubMed: 25022947]

Disclosure: Lokesh Sharma declares no relevant financial relationships with ineligible companies.

Disclosure: Sharon Daley declares no relevant financial relationships with ineligible companies.